Abstract
Rationale
Methamphetamine (MA) increases extracellular dopamine (DA) and at chronic high doses induces toxicity as indicated by decreased expression of tyrosine hydroxylase (TH) and dopamine transporter (DAT). Notably, rats will self-administer MA in escalating quantities producing such toxicity. However, the impact of MA at sub-toxic doses on DA regulation is not well established.
Objective
The temporal dynamics of DA regulation following cessation of sub-toxic escalating and binge doses of non-contingent MA were investigated as changes therein may be associated with escalation of MA intake.
Materials and methods
MA was administered 3×/day using an established 14-day escalating-dose regimen (0.1–4.0 mg/kg) or a single-day binge-style administration (3 × 4 mg/kg). DA tissue content, DA turnover, TH protein, TH phosphorylation, DAT, and vesicular monoamine transporter 2 were measured in nigrostriatal and mesoaccumbens pathways 48 h and 2 weeks after MA cessation.
Results
Changes in striatal DA regulation were limited to increased DA turnover. However, in the mesoaccumbens pathway, escalating MA had biphasic effects. DA was increased in ventral tegmental area (VTA) and decreased in nucleus accumbens at 48 h post-MA while the reverse was seen at 2 weeks. These changes were matched by similar changes in TH protein and, in the VTA, by changes in DAT.
Conclusion
Escalation of MA intake produces both transient and long-lasting effects upon DA, TH, and DAT in the mesoaccumbens pathway. The eventual decrease of DA in the VTA is speculated to contribute to craving for MA and, thus, may be associated with MA escalation and resulting dopaminergic toxicity.
Similar content being viewed by others
References
Argilli E, Sibley DR, Malenka RC, England PM, Bonci A (2008) Mechanism and time course of cocaine-induced long-term potentiation in the ventral tegmental area. J Neurosci 28:9092–9100
Bevilaqua LRM, Graham ME, Dunkley PR, von Nagy-Felsobuki EI, Dickson PW (2001) Phosphorylation of Ser19 alters the conformation of tyrosine hydroxylase to increase the rate of phosphorylation of ser40. J Biol Chem 276:40111–40416
Boger HA, Middaugh LD, Patrick KS, Ramamoorthy S, Denehy ED, Zhu H, Pacchioni AM, Granholm AC, McGinty JF (2007) Long-term consequences of methamphetamine exposure in young adults are exacerbated in glial cell line-derived neurotrophic factor heterozygous mice. J Neurosci 27:8816–8825
Cadet JL, McCoy MT, Cai NS, Krasnova IN, Ladenheim B, Beauvais G, Wilson N, Wood W, Becker KG, Hodges AB (2009) Methamphetamine preconditioning alters midbrain transcriptional responses to methamphetamine-induced injury in the rat striatum. PLoS ONE 4:e7812
Callaghan RC, Cunningham JK, Sajeev G, Kish SJ (2010) Incidence of Parkinson’s disease among hospital patients with methamphetamine-use disorders. Mov Disord 25(14):2333–2339
Cass WA, Manning MW (1999) Recovery of presynaptic dopaminergic functioning in rats treated with neurotoxic doses of methamphetamine. J Neurosci 19:7653–7660
Caudle WM, Richardson JR, Wang MZ, Taylor TN, Guillot TS, McCormack AL et al (2007) Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J Neurosci 27:8138–8148
Caudle WM, Colebrooke RE, Emson PC, Miller GW (2008) Altered vesicular dopamine storage in Parkinson’s disease: a premature demise. Trends Neurosci 31:303–308
Chu P-W, Hadlock GC, Vieira-Brock P, Stout K, Hanson GR, Fleckenstein AE (2010) Methamphetamine alters vesicular monoamine transporter-2 function and potassium-stimulated dopamine release. J Neurochem 115:325–332
Cruz-Muros I, Afonso-Oramas D, Abreu P, Rodriguez M, Gonzalez MC, Gonzalez-Hernandez T (2008) Deglycosylation and subcellular redistribution of VMAT2 in the mesostriatal system during normal aging. Neurobiol Aging 29:1702–1711
Danaceau JP, Deering CE, Day JE, Smeal SJ, Johnson-Davis KL, Fleckenstein AE, Wilkins DG (2007) Persistence of tolerance to methamphetamine-induced monoamine deficits. Eur J Pharmacol 559:46–54
Dobbs LK, Mark GP (2008) Comparison of systemic and local methamphetamine treatment on acetylcholine and dopamine levels in the ventral tegmental area in the mouse. Neuroscience 156:700–711
Dunkley PR, Bobrovskaya L, Graham ME, von Nagy-Felsobuki EI, Dickson PW (2004) Tyrosine hydroxylase phosphorylation: regulation and consequences. J Neurochem 91:1025–1043
Feltenstein MW, See RE (2008) The neurocircuitry of addiction: an overview. Br J Pharmacol 154:261–274
Galloway GP, Singleton EG (2009) How long does craving predict use of methamphetamine? Assessment of use one to seven weeks after the assessment of craving: craving and ongoing methamphetamine use. Subst Abuse 1:63–79
Garwood ER, Bekele W, McCulloch CE, Christine CW (2006) Amphetamine exposure is elevated in Parkinson’s disease. Neurotoxicology 27:1003–1006
Goodwin JS, Larson GA, Swant J, Sen N, Javitch JA, Zahniser NR, DeFelice LJ, Khoshbouei H (2009) Amphetamine and methamphetamine differentially affect dopamine transporters in vitro and in vivo. J Biol Chem 284:2978–2989
Guilarte TR (2001) Is methamphetamine abuse a risk factor in parkinsonism? Neurotoxicology 22:725–731
Haycock JW (1990) Phosphorylation of tyrosine hydroxylase in situ at serine 8, 19, 31, and 40. J Biol Chem 265:11682–11691
Haycock JW, Haycock DA (1991) Tyrosine hydroxylase in rat brain dopaminergic nerve terminals: multiple-site phosphorylation in vivo and in synaptosomes. J Biol Chem 266:5650–5657
Haughey HM, Fleckenstein AE, Hanson GR (1999) Differential regional effects of methamphetamine on the activities of tryptophan and tyrosine hydroxylase. J Neurochem 72:661–668
Jedynak JP, Ali SF, Haycock JW, Hope BT (2002) Acute administration of cocaine regulates the phosphorylation of serine-19, -31, and -40 in tyrosine hydroxylase. J Neurochem 82:382–388
Jones SR, Gainetdinov RR, Jaber M, Giros B, Wightman RM, Caron MG (1998) Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc Natl Acad Sci 95:4029–4034
Koob GF, Volkow ND (2010) Neurocircuitry of addiction. Neuropsychopharmacology 35:217–238
Krasnova IN, Justinova Z, Ladenheim B, Jayanthi S, McCoy MT, Barnes C et al (2010) Methamphetamine self-administration in associated with persistent biochemical alterations in striatal and cortical dopaminergic terminals in the rat. PLoS ONE 5:e8790
Kuczenski R, Segal DS, Melega WP, Lacan G, McCunney SJ (2009) Human methamphetamine pharmacokinetics simulated in the rat: behavioral and neurochemical effects of a 72-h binge. Neuropsychopharmacology 34:2430–2441
Larsen KE, Fon EA, Hastings TG, Edwards RH, Sulzer D (2002) Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis. J Neurosci 22:8951–8960
Lavicky J, Dunn AJ (1993) Corticotropin-releasing factor stimulates catecholamine release in hypothalamus and prefrontal cortex in freely moving rats as assessed by microdialysis. J Neurochem 60:602–612
Letchworth SR, Nader MA, Smith HR, Friedman DP, Porrino LJ (2001) Progression of changes in dopamine transporter binding site density as a result of cocaine self-administration in rhesus monkeys. J Neurosci 21:2799–2807
Lindgren N, Goiny M, Herrera-Marschitz M, Haycock JW, Hokfelt T, Fisone G (2002) Activation of extracellular signal-regulated kinases 1 and 2 by depolarization stimulates tyrosine hydroxylase phosphorylation and dopamine synthesis in rat brain. Eur J Neurosci 15:769–773
Lu L, Wang X, Wu P, Xu C, Zhao M, Morales M, Harvey BK, Hoffer BJ, Shaham Y (2009) Role of ventral tegmental area glial cell line-derived neurotrophic factor in incubation of cocaine craving. Biol Psych 66:137–145
Madden LJ, Flynn CT, Zandonatti MA, May M, Parsons LH, Katner SN et al (2005) Modeling human methamphetamine exposure in nonhuman primates: chronic dosing in the rhesus macaque leads to behavioral and physiological abnormalities. Neuropsychopharmacology 30:350–359
Masserano JM, Baker I, Natsukari N, Wyatt RJ (1996) Chronic cocaine administration increases tyrosine hydroxylase activity in the ventral tegmental area through glutaminergic- and dopaminergic D2-receptor mechanisms. Neurosci Lett 217:73–76
McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA (1998) Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci 18:8417–8422
McCann UD, Kuwabara H, Kumar A, Palermo M, Abbey R, Brasic J et al (2008) Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users. Synapse 62:91–100
Miyazaki I, Asanuma M, Diaz-Corrales FJ, Fukuda M, Kitaichi K, Miyoshi K, Ogawa N (2006) Methamphetamine-induced dopaminergic neurotoxicity is regulated by quinone-formation-related molecules. FASEB J 20:571–573
Mizoguchi H, Yamada K, Mizuno M, Mizuno T, Nitta A, Noda Y, Nabeshima T (2004) Regulations of methamphetamine reward by extracellular signal-regulated kinase 1/2/ets-like gene-1 signaling pathway via the activation of dopamine receptors. Mol Pharm 65:1293–1301
Moszczynska A, Fitzmaurice P, Ang L, Kalasinsky KS, Schmunk GA, Peretti FJ et al (2004) Why is parkinsonism not a feature of human methamphetamine users? Brain 12:363–370
Nimitvalai S, Brodie MS (2010) Reversal of prolonged dopamine inhibition of dopaminergic neurons of the ventral tegmental area. J Pharmacol Exp Ther 333:555–563
Nirenberg MJ, Chan J, Liu Y, Edwards RH, Pickel WM (1996) Ultrastructural localization of the vesicular monoamine transporter-2 in midbrain dopaminergic neurons: potential sites for somatodendritic storage and release of dopamine. J Neurosci 16:4135–4145
O’Callaghan JP, Miller DB (1994) Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 270:741–751
Pruett BS, Salvatore MF (2010) GFR a-1 receptor expression in the aging nigrostriatal and mesoaccumbens pathways. J Neurochem 115:707–715
Riviere GJ, Byrnes KA, Gentry WB, Owens SM (1999) Spontaneous locomotor activity and pharmacokinetics of intravenous methamphetamine and its metabolite amphetamine in the rat. J Pharmacol Exp Ther 291:1220–1226
Rossato JI, Bevilaqua LRM, Izquierdo I, Medina JH, Cammarota M (2009) Dopamine controls persistence of long-term memory storage. Science 325:1017–1020
Salvatore MF, Garcia-Espana A, Goldstein M, Deutch AY, Haycock JW (2000) Stoichiometry of tyrosine hydroxylase phosphorylation in the nigrostriatal and mesolimbic systems in vivo: effects of acute haloperidol and related compounds. J Neurochem 75:225–232
Salvatore MF, Waymire JC, Haycock JW (2001) Depolarization-stimulated catecholamine biosynthesis: involvement of protein kinases and tyrosine hydroxylase phosphorylation sites in situ. J Neurochem 79:349–360
Salvatore MF, Zhang JL, Large DM, Wilson PE, Gash CR, Thomas TC et al (2004) Striatal GDNF administration increases tyrosine hydroxylase phosphorylation in the rat striatum and substantia nigra. J Neurochem 90:245–254
Salvatore MF, Gerhardt GA, Dayton RD, Klein RL, Stanford JA (2009a) Bilateral effects of unilateral GDNF administration on dopamine- and GABA-regulating proteins in the rat nigrostriatal system. Exp Neurol 219:197–207
Salvatore MF, Pruett BS, Spann SL, Dempsey C (2009b) Aging reveals a role for nigral tyrosine hydroxylase ser31 phosphorylation in locomotor activity generation. PLoS ONE 4:e8466
Schwendt M, Rocha A, See RE, Pacchioni AM, McGinty JF, Kalivas PW (2009) Extended methamphetamine self-administration in rats results in a selective reduction of dopamine transporter in the prefrontal cortex and dorsal striatum not accompanied by marked dopaminergic depletion. J Pharmacol Exp Ther 331:555–562
Self DW (2004) Regulation of drug-taking and -seeking behaviors by neuroadaptations in the mesolimbic dopamine system. Neuropharmacology 47:242–255
Segal DS, Kuczenski R, O’Neil ML, Melega WP, Cho AK (2003) Escalating dose methamphetamine pretreatment alters the behavioral and neurochemical profiles associated with exposure to a high-dose methamphetamine binge. Neuropsychopharmacology 28:1730–1740
Shepard JD, Chuang DT, Shaham Y, Morales M (2006) Effect of methamphetamine self-administration on tyrosine hydroxylase and dopamine transporter levels in mesolimbic and nigrostriatal dopamine pathways of the rat. Psychopharmacology 185:505–513
Sonsalla PK, Jochnowitz ND, Zeevalk GD, Oostveen JA, Hall ED (1996) Treatment of mice with methamphetamine produces cell loss in the substantia nigra. Brain Res 738:172–175
Thomas DM, Francescutti-Verbeem DM, Kuhn DM (2008) The newly synthesized pool of dopamine determines the severity of methamphetamine-induced neurotoxicity. J Neurochem 105:605–616
Thomas DM, Francescutti-Verbeem DM, Kuhn DM (2009) Increases in cytoplasmic dopamine compromise the normal resistance of the nucleus accumbens to methamphetamine neurotoxicity. J Neurochem 109:1745–1755
Valjent E, Corvol J-C, Pages C, Besson M-J, Maldonado R, Caboche J (2000) Involvement of the extracellular signal-regulated kinase cascade for cocaine rewarding properties. J Neurosci 20:8701–8709
Volkow ND, Chang L, Wang G-J, Fowler JS, Leonido-Yee M, Franceschi D et al (2001) Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 158:377–382
Volz TJ, Hanson GR, Fleckenstein AE (2007) The role of the plasmalemmal dopamine and vesicular monamine transporters in methamphetamine-induced dopaminergic deficits. J Neurochem 101:883–888
Wallace TL, Gudelsky GA, Vorhees CV (1999) Methamphetamine-induced neurotoxicity alters locomotor activity, stereotypic behavior, and stimulated dopamine release in the rat. J Neurosci 19:9141–9148
Wang J, Carnicella S, Ahmadiantehrani S, He D-Y, Barak S, Kharazia V, Hamida SB, Zapata A, Shippenberg TS, Ron D (2010) Nucleus accumbens-derived glial cell line-derived neurotrophic factor is a retrograde enhancer of dopaminergic tone in the mesocorticolimbic system. J Neurosci 30:14502–14512
Waymire JC, Craviso GL, Lichteig K, Johnston JP, Baldwin C, Zigmond RE (1991) Vasoactive intestinal peptide stimulates catecholamine biosynthesis in isolated adrenal chromaffin cells: evidence for a cyclic AMP-dependent phosphorylation and activation of tyrosine hydroxylase. J Neurochem 57:1313–1324
Weiss F (2005) Neurobiology of craving, conditioned reward and relapse. Curr Op Pharmacol 5:9–19
Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM et al (1996) Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 2:699–703
Wise RA (1996) Neurobiology of addiction. Curr Op Neurobiol 6:243–251
Wise RA (2009) Roles for nigrostriatal–not just mesocorticolimbic–dopamine in reward and addiction. Trends Neurosci 32:517–524
Zahniser NR, Sorkin A (2009) Trafficking of dopamine transporters in psychostimulant actions. Sem Cell Dev Biol 20:411–417
Zaman V, Boger HA, Granholm AC, Rohrer B, Moore A, Buhusi M, Gerhardt GA, Hoffer BJ, Middaugh LD (2008) The nigrostriatal dopamine system of aging GFRalpha-1 heterozygous mice: neurochemistry, morphology and behavior. Eur J Neurosci 28:1557–1568
Zellner MR, Ranaldi R (2010) How conditioned stimuli acquire the ability to activate VTA dopamine cells: a proposed neurobiological component of reward-related learning. Neurosci Behav Rev 34:769–780
Acknowledgments
We thank Clint Kinney, Sandy Spann, Victoria Fields, and Charles Dempsey for their diligent technical work in the project. This work was supported in part by USPSH grant DA06013 from the National Institute on Drug Abuse.
Disclosure/conflict of interest
None
Author information
Authors and Affiliations
Corresponding author
Additional information
Courtney M. Keller and Michael F. Salvatore contributed equally to the manuscript.
Rights and permissions
About this article
Cite this article
Keller, C.M., Salvatore, M.F., Pruett, B.S. et al. Biphasic dopamine regulation in mesoaccumbens pathway in response to non-contingent binge and escalating methamphetamine regimens in the Wistar rat. Psychopharmacology 215, 513–526 (2011). https://doi.org/10.1007/s00213-011-2301-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-011-2301-9